Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Donepezil Hydrochloride Clear all
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

NCT00693004
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Donepezil, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

NCT00988598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01527916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336
View directory record Official record
Conditions
Biomarkers, Pharmacological
Interventions
Huperzine A, Donepezil, Galantamine, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Not listed Phase 1 Interventional

Aricept to Improve Functional Tasks in Vascular Dementia

NCT00457769
View directory record Official record
Conditions
Stroke, Vascular Dementia, Memory Deficits
Interventions
Donepezil and self-generated memory training, Donepezil and experimenter-administered memory training
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

NCT05042102
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT), Placebo medication + Placebo CRT
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment for Early Memory Loss

NCT00042172
View directory record Official record
Conditions
Cognition Disorders, Alzheimer Disease
Interventions
Donepezil, Ginkgo Biloba Extract
Drug
Lead sponsor
University of Iowa
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia

NCT03109314
View directory record Official record
Conditions
Amblyopia
Interventions
Donepezil, Single-letter training, Uncrowd training
Drug · Behavioral
Lead sponsor
Dennis Levi
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 3 Interventional Results available

The Effect of Donepezil on Sedation and Other Symptoms

NCT00352664
View directory record Official record
Conditions
Advanced Cancer
Interventions
Donepezil, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism

NCT01887132
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Donepezil, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
24 Months to 50 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

NCT00987220
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, donepezil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

NCT01955161
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Donepezil on Smoking

NCT01250977
View directory record Official record
Conditions
Smoking
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 3 Interventional Results available

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101 35 mg tablets
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 86 Years
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

NCT00672945
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

NCT00408525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donepezil
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

NCT00293176
View directory record Official record
Conditions
Memory Loss
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
54
States / cities
Albaster, Alabama • Mesa, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Oct 2, 2026, 4:11 AM EDT
Not listed Phase 3 Interventional

Enhancing Rehabilitation After Stroke

NCT00868010
View directory record Official record
Conditions
Ischemic Stroke
Interventions
donepezil, placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Warren, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 2, 2026, 4:11 AM EDT